focus -WSS

focus

author：comprehensive 2025-09-03 05:29:50 - browse：28

From left: Daphne Koller, CEO of Insitro, Vijay Pande of Andreessen Horowitz and scientist Derek Lowe speaking at STAT's Breakthrough Summit in San Francisco. Sarah Gonzalez for STAT

Artificial intelligence is a rapidly improving technology. But its progress in drug development faces an increasingly urgent threat: An unending stream of overheated marketing.

To read of AI’s feats in press releases is to learn of a miracle product on the verge of unraveling biology’s most enduring secrets. It can map molecules and accurately predict how they fit together on computer screens. All you need to get to a cure — as they say in infomercials — is act now!

“I am very worried about the hype,” said Daphne Koller, chief executive of the machine learning drug discovery company Insitro, said during STAT’s Breakthrough West Summit in San Francisco last week. “People think (the breakthrough) is going to happen tomorrow.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： George Santos makes 1st court appearance after pleading not guilty to 13 counts
Next article： Bernie Sanders is gearing up to subpoena pharma CEOs

WSS

Vertex non

Why you shouldn’t ask, “What country has the best health care?”

Merck CEO won’t testify in Senate, citing no expertise in drug prices

What we owe ALS patients — and why one company fell short

Experts study whether long Covid risk adds up with each reinfection

The United States is paying nearly triple for new Covid vaccines

hotspot

focus

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

leisure time

The high cost of giving birth even with insurance

Will an HIV vaccine ever be a reality?

Jerome Adams on the need for new antivirals for Covid

The United States is paying nearly triple for new Covid vaccines

BioMarin wins approval for gene therapy to treat hemophilia A

Lawsuit highlights wrinkle for disputes over surprise medical bills

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

What we owe ALS patients — and why one company fell short

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Reconstructing family trees of blood cells may help predict disease

knowledge

Syphilis numbers in the United States reach record heights

FTC sues over Novant Health acquisition of two N.C. hospitals

What will Novo Nordisk's VC do with its influx of cash?

2023 Nobel Prize in Medicine goes to Karikó and Weissman

With Roe v Wade overturned, abortion providers work to adapt

Investment in vaccine development is lagging, report finds

leisure time

hotspot

hotspot

Wikipedia